Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline hails ‘good start to 2010’

GlaxoSmithKline hails ‘good start to 2010’

30th April 2010

GlaxoSmithKline has expressed satisfaction with its fiscal performance for the first quarter of 2010, after reporting improved sales in the first quarter.

The company’s turnover during the first three months of 2010 came to 7.4 billion pounds, up 13 per cent compared to the first quarter of 2009, with pharmaceutical sales increasing by 14 per cent.

It credited this growth to improved sales of vaccines, respiratory and dermatology treatments, while demand for pandemic influenza products also played a key role.

In his quarterly review, GlaxoSmithKline chief executive officer Andrew Witty added that new executive appointments made during the quarter will also help to position the company for longer-term success.

He said: “GlaxoSmithKline has made a good start to 2010 and this provides further confirmation that our strategy is working.”

Earlier this month, the pharmaceutical company was granted approval from regulators to market its refractory chronic lymphocytic leukaemia treatment Arzerra in Europe.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.